As Amicus Therapeutics (FOLD) Shares Rose, Holder Perceptive Advisors Lifted Its Position; Schein Henry Co (HSIC) Shareholder Thompson Investment Management Increased Its Holding by $471,500 as Share Price Rose

January 6, 2018 - By Winifred Garcia

Thompson Investment Management Inc increased its stake in Schein Henry Inc Co (HSIC) by 74.19% based on its latest 2017Q3 regulatory filing with the SEC. Thompson Investment Management Inc bought 5,750 shares as the company’s stock rose 5.77% with the market. The institutional investor held 13,500 shares of the health care company at the end of 2017Q3, valued at $1.11 million, up from 7,750 at the end of the previous reported quarter. Thompson Investment Management Inc who had been investing in Schein Henry Inc Co for a number of months, seems to be bullish on the $11.51 billion market cap company. The stock increased 1.59% or $1.15 during the last trading session, reaching $73.33. About 1.30M shares traded. Henry Schein, Inc. (NASDAQ:HSIC) has risen 4.05% since January 6, 2017 and is uptrending. It has underperformed by 12.65% the S&P500.

Joseph Edelman increased its stake in Amicus Therapeutics Inc (FOLD) by 3.42% based on its latest 2017Q3 regulatory filing with the SEC. Perceptive Advisors Llc bought 591,925 shares as the company’s stock rose 23.92% with the market. The hedge fund run by Joseph Edelman held 17.89 million shares of the health care company at the end of 2017Q3, valued at $269.76M, up from 17.30M at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Amicus Therapeutics Inc for a number of months, seems to be bullish on the $2.48B market cap company. The stock decreased 3.43% or $0.53 during the last trading session, reaching $14.91. About 2.37 million shares traded or 4.72% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since January 6, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 20 analyst reports since August 18, 2015 according to SRatingsIntel. Goldman Sachs initiated it with “Neutral” rating and $10 target in Wednesday, March 30 report. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Buy” rating by Cowen & Co on Monday, August 7. The company was maintained on Tuesday, July 11 by Cowen & Co. The rating was downgraded by Zacks to “Buy” on Tuesday, August 18. The firm has “Buy” rating by Cowen & Co given on Tuesday, September 1. Robert W. Baird upgraded the stock to “Outperform” rating in Tuesday, January 24 report. On Wednesday, July 12 the stock rating was maintained by Robert W. Baird with “Outperform”. The stock has “Buy” rating by Cowen & Co on Sunday, June 25. The firm earned “Neutral” rating on Thursday, April 14 by Robert W. Baird. The stock has “Buy” rating by Janney Capital on Tuesday, March 8.

Since October 12, 2017, it had 0 buys, and 8 insider sales for $9.26 million activity. 7,000 shares valued at $99,740 were sold by Quimi Daphne on Thursday, October 12. $570,132 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Baird William D III. RAAB MICHAEL also sold $142,534 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Thursday, October 12. $71,268 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Barth Jay. The insider Do Hung sold 50,194 shares worth $715,360.

Investors sentiment increased to 2.33 in 2017 Q3. Its up 1.10, from 1.23 in 2017Q2. It increased, as 16 investors sold FOLD shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Pointstate Capital Lp reported 0.21% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Ohio-based Victory Cap Mngmt has invested 0.08% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Next Fincl Group Incorporated owns 2,625 shares. Massachusetts Svcs Ma invested in 0% or 676,117 shares. The California-based California Employees Retirement System has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Jane Street Limited Co reported 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Sectoral Asset Management reported 2.41 million shares or 4.69% of all its holdings. Sg Americas Secs Ltd Liability Co holds 10,888 shares or 0% of its portfolio. The California-based Franklin Resource Inc has invested 0.02% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Acuta Ltd holds 0.81% or 300,000 shares in its portfolio. Moore Cap Mgmt Limited Partnership holds 100,000 shares. Cubist Systematic Strategies Ltd Liability Corporation, a Connecticut-based fund reported 15,300 shares. D E Shaw Company reported 0.1% stake. Eagle Asset holds 0.23% or 2.70 million shares in its portfolio. Neuberger Berman Ltd Liability Com has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Perceptive Advisors Llc, which manages about $2.09B and $2.62B US Long portfolio, decreased its stake in Versartis Inc (NASDAQ:VSAR) by 2.52M shares to 1.89 million shares, valued at $4.63M in 2017Q3, according to the filing. It also reduced its holding in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 43,959 shares in the quarter, leaving it with 1.79M shares, and cut its stake in Evolent Health Inc.

Among 19 analysts covering Henry Schein Inc. (NASDAQ:HSIC), 11 have Buy rating, 1 Sell and 7 Hold. Therefore 58% are positive. Henry Schein Inc. had 42 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Henry Schein, Inc. (NASDAQ:HSIC) earned “Neutral” rating by Robert W. Baird on Friday, October 14. As per Monday, September 12, the company rating was initiated by Bank of America. The firm has “Buy” rating by Deutsche Bank given on Friday, December 8. The company was maintained on Tuesday, November 7 by Robert W. Baird. Gabelli downgraded the stock to “Hold” rating in Friday, November 6 report. The rating was maintained by Barrington Research with “Outperform” on Wednesday, February 22. Credit Suisse maintained the stock with “Hold” rating in Tuesday, November 28 report. Jefferies maintained the shares of HSIC in report on Tuesday, August 22 with “Hold” rating. The stock of Henry Schein, Inc. (NASDAQ:HSIC) earned “Neutral” rating by Northcoast on Tuesday, December 6. Leerink Swann maintained the shares of HSIC in report on Tuesday, November 7 with “Market Perform” rating.

Since September 6, 2017, it had 0 insider purchases, and 1 insider sale for $366,756 activity.

Thompson Investment Management Inc, which manages about $2.99 billion and $536.27 million US Long portfolio, decreased its stake in Nxp Semiconductors N V Com (NASDAQ:NXPI) by 63,410 shares to 3,030 shares, valued at $343,000 in 2017Q3, according to the filing. It also reduced its holding in Coca Cola Co (NYSE:KO) by 9,393 shares in the quarter, leaving it with 41,658 shares, and cut its stake in Exact Sciences Corp Com (NASDAQ:EXAS).

Investors sentiment increased to 7.15 in Q3 2017. Its up 5.99, from 1.16 in 2017Q2. It increased, as 47 investors sold HSIC shares while 15 reduced holdings. 66 funds opened positions while 377 raised stakes. 279.70 million shares or 306.41% more from 68.82 million shares in 2017Q2 were reported. Retirement Of Alabama holds 0.05% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC) for 115,447 shares. M Holdg Securities holds 0.07% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC) for 2,552 shares. Old Mutual Customised Solutions (Proprietary) Ltd holds 0.09% or 8,000 shares in its portfolio. Liberty Mutual Grp Asset Management Inc holds 0.03% or 6,424 shares in its portfolio. Private Trust Company Na holds 5,174 shares or 0.09% of its portfolio. King Luther Mngmt stated it has 6,038 shares or 0% of all its holdings. Gateway Invest Advisers Lc has invested 0.05% in Henry Schein, Inc. (NASDAQ:HSIC). Moreover, Greenleaf Tru has 0% invested in Henry Schein, Inc. (NASDAQ:HSIC). Deutsche State Bank Ag reported 389,649 shares stake. Gsa Cap Prtnrs Llp owns 15,511 shares or 0.09% of their US portfolio. Lmr Prtn Ltd Liability Partnership stated it has 0.06% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC). 442 are owned by Lazard Asset Limited Liability Corp. Eads And Heald Invest Counsel accumulated 15,095 shares. Schroder Inv Management Gru owns 637,649 shares or 0.09% of their US portfolio. Ubs Asset Mngmt Americas Inc has 0.05% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 611,400 shares.